St. Jude Medical downgraded to Underperform from Neutral at Cowen Cowen downgraded St. Jude based on expectations the company will lose CRM share starting in 2013. Additionally, the firm sees risk that Durata will be the subject of a Class 1 recall, which could pressure performance.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
Leerink medical devices analyst holds an analyst/industry conference call Medical Devices Analyst Antalffy discusses the ultimate market opportunity for leadless pacers and compares Medtronic vs St. Jude Medical on an Analyst/Industry conference call to be held on September 24 at 2 pm.
St. Jude Medical recent weakness a buying opportunity, says Barclays Barclays said St. Jude Medical weakness is a buying opportunity. The analyst said CardioMEMS is underappreciated by the Street and valuation compelling given sequential revenue growth. Shares are Overweight rated.